Raras
Buscar doenças, sintomas, genes...
Doença do metabolismo do ciclo da ureia e destoxificação da amônia
ORPHA:79167CID-10 · E72.2DOENÇA RARA

É um erro genético no metabolismo, presente desde o nascimento. Caracteriza-se pela falta de uma das enzimas (proteínas que ajudam nas reações químicas do corpo) essenciais para o ciclo da ureia. O ciclo da ureia é um processo importante que o corpo usa para eliminar substâncias tóxicas. Como resultado, uma substância chamada amônia se acumula no organismo, o que pode ser prejudicial.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É um erro genético no metabolismo, presente desde o nascimento. Caracteriza-se pela falta de uma das enzimas (proteínas que ajudam nas reações químicas do corpo) essenciais para o ciclo da ureia. O ciclo da ureia é um processo importante que o corpo usa para eliminar substâncias tóxicas. Como resultado, uma substância chamada amônia se acumula no organismo, o que pode ser prejudicial.

🏥
SUS: Cobertura parcialScore: 40%
Triagem neonatal (Fase 2)Centros em: PA, PR, SC, RS, ES +8CID-10: E72.2
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (7)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)nutritional
0301070040
Atendimento em reabilitação — doenças raras
+1 outros procedimentos
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
47 sintomas
🫃
Digestivo
30 sintomas
📏
Crescimento
16 sintomas
🫘
Rins
8 sintomas
🧬
Pele e cabelo
6 sintomas
🩸
Sangue
6 sintomas

+ 134 sintomas em outras categorias

Características mais comuns

Deficiência intelectual, leve
Isquemia cerebral
Maneirismos repetitivos anormais
Episódios psicóticos
Microcefalia
Fala pobre
264sintomas
Sem dados (264)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 264 características clínicas mais associadas, ordenadas por frequência.

Deficiência intelectual, leveIntellectual disability, mild
Isquemia cerebralCerebral ischemia
Maneirismos repetitivos anormaisAbnormal repetitive mannerisms
Episódios psicóticosPsychotic episodes
MicrocefaliaMicrocephaly

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos33publicações
Pico20259 papers
Linha do tempo
20202015Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: MS/MS — citrulina, ácido argininossuccínico
Fase 2 do PNTNin_rollout
Incidência no Brasil: 1:30.000

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

11 genes identificados com associação a esta condição.

CA5ACarbonic anhydrase 5A, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial carbonic anhydrase that catalyzes the reversible conversion of carbon dioxide to bicarbonate/HCO3 (PubMed:24530203, PubMed:8356065). Mitochondria are impermeable to HCO3, and thus this intramitochondrial carbonic anhydrase is pivotal in providing HCO3 for multiple mitochondrial enzymes that catalyze the formation of essential metabolites of intermediary metabolism in the urea and Krebs cycles (PubMed:24530203)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Reversible hydration of carbon dioxide
MECANISMO DE DOENÇA

Hyperammonemia due to carbonic anhydrase VA deficiency

An autosomal recessive inborn error of metabolism, clinically characterized by infantile hyperammonemic encephalopathy. Metabolic abnormalities include hypoglycemia, hyperlactatemia, metabolic acidosis and respiratory alkalosis.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency
HGNC:1377UniProt:P35218
ASLArgininosuccinate lyaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible cleavage of L-argininosuccinate to fumarate and L-arginine, an intermediate step reaction in the urea cycle mostly providing for hepatic nitrogen detoxification into excretable urea as well as de novo L-arginine synthesis in nonhepatic tissues (PubMed:11747432, PubMed:11747433, PubMed:22081021, PubMed:2263616, PubMed:9045711). Essential regulator of intracellular and extracellular L-arginine pools. As part of citrulline-nitric oxide cycle, forms tissue-specific multiprot

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Argininosuccinic aciduria

An autosomal recessive disorder of the urea cycle. The disease is characterized by mental and physical retardation, liver enlargement, skin lesions, dry and brittle hair showing trichorrhexis nodosa microscopically and fluorescing red, convulsions, and episodic unconsciousness.

OUTRAS DOENÇAS (1)
argininosuccinic aciduria
HGNC:746UniProt:P04424
MCCC1Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Biotin-attachment subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 1 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.9 TPM
Ovário
28.1 TPM
Glândula adrenal
26.9 TPM
Tireoide
25.8 TPM
Nervo tibial
25.6 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 1 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6936UniProt:Q96RQ3
ARG1Arginase-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available int

LOCALIZAÇÃO

CytoplasmCytoplasmic granule

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Argininemia

A rare autosomal recessive disorder of the urea cycle. Arginine is elevated in the blood and cerebrospinal fluid, and periodic hyperammonemia occurs. Clinical manifestations include developmental delay, seizures, intellectual disability, hypotonia, ataxia and progressive spastic quadriplegia.

OUTRAS DOENÇAS (1)
arginase deficiency
HGNC:663UniProt:P05089
ASS1Argininosuccinate synthaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

One of the enzymes of the urea cycle, the metabolic pathway transforming neurotoxic amonia produced by protein catabolism into inocuous urea in the liver of ureotelic animals. Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP and together with ASL it is responsible for the biosynthesis of arginine in most body tissues

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Citrullinemia 1

The classic form of citrullinemia, an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. It is a disorder of the urea cycle, usually manifesting in the first few days of life. Affected infants appear normal at birth, but as ammonia builds up in the body they present symptoms such as lethargy, poor feeding, vomiting, seizures and loss of consciousness. Less commonly, a milder form can develop later in childhood or adulthood.

OUTRAS DOENÇAS (3)
citrullinemia type Iacute neonatal citrullinemia type Iadult-onset citrullinemia type I
HGNC:758UniProt:P00966
SLC25A13Electrogenic aspartate/glutamate antiporter SLC25A13, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial electrogenic aspartate/glutamate antiporter that favors efflux of aspartate and entry of glutamate and proton within the mitochondria as part of the malate-aspartate shuttle (PubMed:11566871, PubMed:38937634, PubMed:38945283, PubMed:39419476). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then dissociating from the substrate binding site before the second substrate binds for transport in the opposite direction (PubMed:389376

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Aspartate and asparagine metabolismMalate-aspartate shuttle
MECANISMO DE DOENÇA

Citrin deficiency, adolescent or adult onset

An autosomal recessive metabolic disorder characterized by elevated serum and urine citrulline levels, ammonia intoxication, and neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
44.3 TPM
Brain Spinal cord cervical c-1
21.7 TPM
Skin Sun Exposed Lower leg
21.1 TPM
Cervix Endocervix
19.9 TPM
Glândula adrenal
19.0 TPM
OUTRAS DOENÇAS (3)
citrullinemia, type II, adult-onsetneonatal intrahepatic cholestasis due to citrin deficiencycitrullinemia type II
HGNC:10983UniProt:Q9UJS0
CPS1Carbamoyl-phosphate synthase [ammonia], mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell

LOCALIZAÇÃO

MitochondrionNucleus, nucleolusCell membrane

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Carbamoyl phosphate synthetase 1 deficiency

An autosomal recessive disorder of the urea cycle causing hyperammonemia. It can present as a devastating metabolic disease dominated by severe hyperammonemia in neonates or as a more insidious late-onset condition, generally manifesting as life-threatening hyperammonemic crises under catabolic situations. Clinical features include protein intolerance, intermittent ataxia, seizures, lethargy, developmental delay and intellectual disability.

OUTRAS DOENÇAS (1)
carbamoyl phosphate synthetase I deficiency disease
HGNC:2323UniProt:P31327
NAGSN-acetylglutamate synthase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in the regulation of ureagenesis by producing the essential cofactor N-acetylglutamate (NAG), thus modulating carbamoylphosphate synthase I (CPS1) activity

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
NAGS variants cause NAGS deficiency
MECANISMO DE DOENÇA

N-acetylglutamate synthase deficiency

Rare autosomal recessively inherited metabolic disorder leading to severe neonatal or late-onset hyperammonemia without increased excretion of orotic acid. Clinical symptoms are somnolence, tachypnea, feeding difficulties, a severe neurologic presentation characterized by uncontrollable movements, developmental delay, visual impairment, failure to thrive and hyperammonemia precipitated by the introduction of high-protein diet or febrile illness.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
39.8 TPM
Fibroblastos
17.8 TPM
Tireoide
11.8 TPM
Intestino delgado
9.3 TPM
Rim - Córtex
6.1 TPM
OUTRAS DOENÇAS (1)
hyperammonemia due to N-acetylglutamate synthase deficiency
HGNC:17996UniProt:Q8N159
GLUD1Glutamate dehydrogenase 1, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Mitochondrial glutamate dehydrogenase that catalyzes the conversion of L-glutamate into alpha-ketoglutarate. Plays a key role in glutamine anaplerosis by producing alpha-ketoglutarate, an important intermediate in the tricarboxylic acid cycle (PubMed:11032875, PubMed:11254391, PubMed:16023112, PubMed:16959573). Plays a role in insulin homeostasis (PubMed:11297618, PubMed:9571255). May be involved in learning and memory reactions by increasing the turnover of the excitatory neurotransmitter gluta

LOCALIZAÇÃO

MitochondrionEndoplasmic reticulum

VIAS BIOLÓGICAS (3)
Glutamate and glutamine metabolismTranscriptional activation of mitochondrial biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Hyperinsulinemic hypoglycemia, familial, 6

A form of hyperinsulinemic hypoglycemia, a clinically and genetically heterogeneous disorder characterized by inappropriate insulin secretion from the pancreatic beta-cells in the presence of low blood glucose levels. HHF6 is an autosomal dominant form characterized by hypoglycemia due to congenital hyperinsulinism combined with persistent hyperammonemia. Clinical features include loss of consciousness due to hypoglycemia, hypoglycemic seizures, and mental retardation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
306.2 TPM
Brain Nucleus accumbens basal ganglia
296.5 TPM
Brain Anterior cingulate cortex BA24
269.5 TPM
Brain Caudate basal ganglia
266.0 TPM
Cérebro - Amígdala
254.6 TPM
OUTRAS DOENÇAS (1)
hyperinsulinism-hyperammonemia syndrome
HGNC:4335UniProt:P00367
OTCOrnithine transcarbamylase, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline (PubMed:2556444, PubMed:6372096, PubMed:8112735). The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion (PubMed:2556444)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Urea cycleMitochondrial protein import
MECANISMO DE DOENÇA

Ornithine carbamoyltransferase deficiency

An X-linked disorder of the urea cycle which causes a form of hyperammonemia. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. The disorder is treatable with supplemental dietary arginine and low protein diet. The arbitrary classification of patients into the 'neonatal' group (clinical hyperammonemia in the first few days of life) and 'late' onset (clinical presentation after the neonatal period) has been used to differentiate severe from mild forms.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
51.3 TPM
Intestino delgado
16.4 TPM
Cólon transverso
1.6 TPM
Testículo
1.1 TPM
Fallopian Tube
1.0 TPM
OUTRAS DOENÇAS (1)
ornithine carbamoyltransferase deficiency
HGNC:8512UniProt:P00480
SLC25A15Mitochondrial ornithine transporter 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial ornithine-citrulline antiporter (Probable) (PubMed:12807890, PubMed:22262851). Catalyzes the exchange between cytosolic ornithine and mitochondrial citrulline plus an H(+), the proton compensates the positive charge of ornithine thus leading to an electroneutral transport. Plays a crucial role in the urea cycle, by connecting the cytosolic and the intramitochondrial reactions of the urea cycle (Probable) (PubMed:12807890, PubMed:22262851). Lysine and arginine are also transported b

LOCALIZAÇÃO

Mitochondrion inner membraneMitochondrion membrane

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

An autosomal recessive disorder of the urea cycle characterized by onset in early life. The acute phase of the disease is characterized by vomiting, ataxia, lethargy, confusion, and coma. Chronic clinical manifestations include hypotonia, developmental delay, progressive encephalopathy with mental regression, and spastic paraparesis with pyramidal signs.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
30.0 TPM
Fibroblastos
13.7 TPM
Pâncreas
13.3 TPM
Testículo
12.7 TPM
Linfócitos
11.6 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
ornithine translocase deficiency
HGNC:10985UniProt:Q9Y619

Variantes genéticas (ClinVar)

689 variantes patogênicas registradas no ClinVar.

🧬 CA5A: GRCh37/hg19 16q24.2-24.3(chr16:87640702-89570635)x1 ()
🧬 CA5A: GRCh37/hg19 16q24.1-24.2(chr16:85281141-88194304)x1 ()
🧬 CA5A: NM_001739.2(CA5A):c.434T>C (p.Val145Ala) ()
🧬 CA5A: NM_001739.2(CA5A):c.472C>T (p.His158Tyr) ()
🧬 CA5A: GRCh37/hg19 16q11.2-24.3(chr16:46432879-90294753)x3 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença do metabolismo do ciclo da ureia e destoxificação da amônia

Centros de Referência SUS

21 centros habilitados pelo SUS para Doença do metabolismo do ciclo da ureia e destoxificação da amônia

Centros para Doença do metabolismo do ciclo da ureia e destoxificação da amônia

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Nitrogen Scavengers: History, Clinical Considerations and Future Prospects.

Journal of inherited metabolic disease2025 Nov

Nitrogen scavengers play a critical role in treating acute and chronic hyperammonemia, especially in urea cycle disorders (UCDs), where impaired ammonia detoxification leads to toxic nitrogen accumulation. These agents complement low-protein diets and urea cycle intermediates. Sodium benzoate and sodium phenylacetate are the main scavengers, conjugating with glycine and glutamine to form hippurate and phenylacetylglutamine, which are excreted in urine. This therapeutic approach, introduced in the 1980s, was based on early findings linking benzoate to reduced urea excretion. Nitrogen scavengers are also used in secondary hyperammonemia from organic acidemias and fatty acid oxidation disorders, though they may become increasingly ineffective in progressing liver failure due to their reliance on hepatocyte function. To improve tolerability, phenylbutyrate was developed as an oral alternative to phenylacetate and is available in sodium-bound and prodrug forms, but issues with taste and side effects persist. While effective, current treatments target nitrogenous waste products rather than ammonia directly, offering an avenue of future drug development for UCDs. This review discusses the chemical properties, clinical use, and limitations of nitrogen scavengers, hereby focusing on phenylacetate and related substances, and highlights the need for improved therapies, including approaches that directly target ammonia removal. For the benefit of readers already experienced in nitrogen scavengers for UCDs, we also include considerations concerning the use of these drugs in animal experiments and a viewpoint on ornithine phenylacetate as a related substance.

#2

The Current Status of Adult Patients With Urea Cycle Disorders in Japan: From the Nation-Wide Study.

Journal of inherited metabolic disease2025 Nov

Urea cycle disorders (UCDs) are rare inherited metabolic diseases characterized by defective detoxification of nitrogen, leading to hyperammonemia and neurological complications. While pediatric UCDs have been extensively studied in Japan, data on adult patients remain limited. This study aims to evaluate the current status of Japanese adult UCD patients, hereby comparing long-term outcomes after neonatal/infantile or late onset in a new nationwide study investigating clinical manifestations and management. In total, we collected data of 116 adult UCD patients diagnosed and/or treated at various institutions, combining this new cohort (34 UCD patients between January 2010 and December 2022) with data from a previous nationwide study (82 UCD patients between January 2000 and March 2018). Among 116 adult UCD patients, ornithine transcarbamylase deficiency was the most common subtype (N = 69). Hyperammonemia occurred in 91.4% of patients, and intellectual disability was present in 50.0%. Patients generally showed reduced final height and BMI compared to Japanese controls, particularly among females and those with infantile-onset UCDs. Peak ammonia levels ≥ 360 μmol/L were significantly associated with intellectual disability. Liver transplantation (LT) was performed in 20 patients, and although it helped to avoid hyperammonemia, it did not statistically improve neurocognitive outcomes in patients with peak ammonia < 360 μmol/L. This study provides the first comprehensive overview of adult UCD patients in Japan, highlighting frequent growth impairment and variable cognitive outcomes. LT improves metabolic control but cannot prevent intellectual disability in all patients. These findings underscore the need for early diagnosis, individualized treatment strategies, and long-term follow-up into adulthood.

#3

Hyperammonemia in urea cycle disorders: A toxic metabolite for the brain.

Pediatrics international : official journal of the Japan Pediatric Society2025

Ammonia can easily cross the blood-brain barrier in its non-ionized form, leading to significant accumulation in the brain during severe hyperammonemia. Excess ammonia is highly toxic to the brain and can cause neurological dysfunctions, such as tremors, ataxia, seizures, coma, and even death. Hyperammonemia is often the primary manifestation of urea cycle disorders (UCDs), a group of inherited metabolic disorders characterized by impaired nitrogen detoxification due to dysfunctions in urea cycle-related enzymes and transporters. Patients with complete deficiencies of urea cycle enzymes typically present with lethargy, hypothermia, anorexia, seizures, abnormal respiratory patterns (hyperventilation or hypoventilation), neurologic posturing, and coma, along with hyperammonemia within a few days after birth. This condition, classified as the neonatal-onset type, frequently results in severe hyperammonemic encephalopathy (≥600 μg/dL [360 μmol/L]) at onset. Hyperammonemia with blood ammonia levels of 600 μg/dL (360 μmol/L) or higher causes significant brain damage. Therefore, at this threshold, hemodialysis is indicated to rapidly remove ammonia and mitigate its harmful effects on the brain. However, even when neonatal-onset UCD patients undergo a combination of hemodialysis and liver transplantation at the onset of severe hyperammonemia (≥600 μg/dL [360 μmol/L]), the neuroprotective effects remain limited. This review aims to describe the pathophysiology of hyperammonemia and UCDs, the impact of hyperammonemia on the brain in UCDs, the role of current therapeutic strategies, and the challenges associated with future treatments for UCDs.

#4

Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient-Derived Liver Disease Models.

Journal of inherited metabolic disease2025 May

Urea cycle disorders (UCDs) are inherited diseases causing recurrent life-threatening metabolic decompensations due to impaired hepatic ammonia detoxification and decreased ureagenesis. Ornithine transcarbamylase (OTC) deficiency (OTCD) is X-linked and the most common and often fatal UCD. In male hemizygous patients, disease severity primarily depends on the pathogenic sequence variant, while in heterozygous females, disease severity also depends on the X-chromosomal inactivation (XCI) pattern. Females with unfavorable XCI predominantly expressing the mutant OTC protein may be severely affected. Here, we investigated a novel treatment strategy for OTCD since there is an unmet need for better therapies. In the first step, we performed a high throughput screening (HTS) using a diversity library with 10 000 chemical compounds to identify pharmacological chaperone (PC) candidates that stabilize purified wild-type OTC. Stratification of our HTS results revealed five potential PCs, which were selected for further experimentation in cellular systems using primary human hepatocytes (PHHs) and human induced pluripotent stem cell (hiPSC)-derived hepatocytes (hiPSC-Heps) from healthy controls and OTCD patients. Two PCs-PC1 and PC4-increased OTC protein stability and activity in control hiPSC-Heps, while PC4 in addition increased OTC activity in patient-derived PHHs from a female OTCD patient with unfavorable XCI. Finally, PC1 and PC4 both significantly increased ureagenesis in patient-derived PHHs. To conclude, we identified two PCs that stabilized wild-type OTC and enhanced enzyme activity and ureagenesis. Our work suggests that PCs could provide a novel treatment strategy for OTCD specifically in females with unfavorable XCI.

#5

Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report.

Radiation oncology journal2025 Dec

Ornithine transcarbamylase (OTC) deficiency is a rare urea cycle disorder that impairs ammonia detoxification, increasing the risk of hyperammonemic crises under metabolic stress. While chemotherapy-related risks have been reported, data on the safety of ionizing radiation therapy (RT) in this population are limited. This case describes a 30-year-old woman with late-onset OTC deficiency diagnosed with right-sided ductal carcinoma in situ. She underwent segmental mastectomy followed by adjuvant 3D conformal RT (40 Gy in 15 fractions with a concomitant boost to 48 Gy). Her multidisciplinary care involved preoperative hydration, close nutritional monitoring, and serial ammonia measurements. She completed RT without treatment interruptions or signs of hyperammonemia. This case illustrates that breast RT can be delivered safely in patients with OTC deficiency with a multidisciplinary, preventative approach. To our knowledge, this is the first report describing RT planning and metabolic surveillance in this population.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 33

2025

Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report.

Radiation oncology journal
2025

Hyperuricemia increases susceptibility to chronic kidney injury exacerbation via autophagic flux blockade-mediated ammonia death pathway.

Journal of advanced research
2025

Nitrogen Scavengers: History, Clinical Considerations and Future Prospects.

Journal of inherited metabolic disease
2025

The Current Status of Adult Patients With Urea Cycle Disorders in Japan: From the Nation-Wide Study.

Journal of inherited metabolic disease
2025

Current Treatment Modalities for Urea Cycle Disorders.

Paediatric drugs
2025

Amino Acid Metabolism in Liver Mitochondria: From Homeostasis to Disease.

Metabolites
2025

Hyperammonemia in urea cycle disorders: A toxic metabolite for the brain.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient-Derived Liver Disease Models.

Journal of inherited metabolic disease
2025

A novel de novo missense OTC mutation in an Iranian girl: a case report.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2024

Quo vadis ureagenesis disorders? A journey from 90 years ago into the future.

Journal of inherited metabolic disease
2022

Challenges of managing ornithine transcarbamylase deficiency in female heterozygotes.

Molecular genetics and metabolism reports
2021

Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys.

Molecular therapy. Methods &amp; clinical development
2021

[Aciduria argininosuccínica: informe de un caso de inicio neonatal].

Archivos argentinos de pediatria
2021

Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.

Journal of inherited metabolic disease
2020

Primary hyperammonaemia: Current diagnostic and therapeutic strategies.

Journal of mother and child
2021

Metabolic basis and treatment of citrin deficiency.

Journal of inherited metabolic disease
2020

Therapeutic effect of N-carbamylglutamate in CPS1 deficiency.

Molecular genetics and metabolism reports
2020

Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis.

Nutrients
2020

Ammonia uptake by transmembrane pH gradient poly(isoprene)-block-poly(ethylene glycol) polymersomes.

Soft matter
2020

Inborn errors of enzymes in glutamate metabolism.

Journal of inherited metabolic disease
2019

Simultaneous quantification of 48 plasma amino acids by liquid chromatography-tandem mass spectrometry to investigate urea cycle disorders.

Clinica chimica acta; international journal of clinical chemistry
2019

Challenges in diagnosing and managing adult patients with urea cycle disorders.

Journal of inherited metabolic disease
2019

Malnutrition with hypoaminoacidemia in a 22-year-old pregnant patient masking a likely ornithine transcarbamylase deficiency.

Clinical nutrition ESPEN
2019

Hepatic glutamine synthetase augmentation enhances ammonia detoxification.

Journal of inherited metabolic disease
2019

Comprehensive characterization of ureagenesis in the spfash mouse, a model of human ornithine transcarbamylase deficiency, reveals age-dependency of ammonia detoxification.

Journal of inherited metabolic disease
2019

Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia.

Journal of inherited metabolic disease
2018

Medium-chain triglycerides supplement therapy with a low-carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult-onset type II citrullinemia.

Journal of inherited metabolic disease
2018

Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency.

Virchows Archiv : an international journal of pathology
2018

Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia.

Proceedings of the National Academy of Sciences of the United States of America
2016

Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001-2013.

Orphanet journal of rare diseases
2016

In vivo monitoring of urea cycle activity with (13)C-acetate as a tracer of ureagenesis.

Molecular genetics and metabolism
2015

Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis.

Scientific reports
2015

Recent advances in the treatment of hyperammonemia.

Advanced drug delivery reviews

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença do metabolismo do ciclo da ureia e destoxificação da amônia.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença do metabolismo do ciclo da ureia e destoxificação da amônia

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Nitrogen Scavengers: History, Clinical Considerations and Future Prospects.
    Journal of inherited metabolic disease· 2025· PMID 41163474mais citado
  2. The Current Status of Adult Patients With Urea Cycle Disorders in Japan: From the Nation-Wide Study.
    Journal of inherited metabolic disease· 2025· PMID 41074536mais citado
  3. Hyperammonemia in urea cycle disorders: A toxic metabolite for the brain.
    Pediatrics international : official journal of the Japan Pediatric Society· 2025· PMID 40464331mais citado
  4. Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient-Derived Liver Disease Models.
    Journal of inherited metabolic disease· 2025· PMID 40421674mais citado
  5. Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report.
    Radiation oncology journal· 2025· PMID 41486901mais citado
  6. [A 71-year-old woman with adult-onset type II citrullinemia, initially presenting with normal blood ammonia levels].
    Rinsho Shinkeigaku· 2026· PMID 41371681recente
  7. [Hyperammonemia and metabolic-associated fatty liver disease: a complex relationship].
    Vopr Pitan· 2025· PMID 41263349recente
  8. [Clinical characteristics and efficacy of glyceryl phenylbutyrate treatment in 20 pediatric patients with urea cycle disorder].
    Zhonghua Er Ke Za Zhi· 2025· PMID 40835254recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79167(Orphanet)
  2. MONDO:0004739(MONDO)
  3. GARD:7837(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1585743(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença do metabolismo do ciclo da ureia e destoxificação da amônia
Compêndio · Raras BR

Doença do metabolismo do ciclo da ureia e destoxificação da amônia

ORPHA:79167 · MONDO:0004739
🇧🇷 Brasil SUS
Triagem
MS/MS — citrulina, ácido argininossuccínico
PNTN
Fase 2
Incidência BR
1:30.000
Geral
CID-10
E72.2 · Distúrbios do metabolismo do ciclo da uréia
MedGen
UMLS
C0154246
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades